HRP20030504B1 - Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof - Google Patents

Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof

Info

Publication number: HRP20030504B1
Authority: HR; Croatia
Prior art keywords: utilization; compounds; quinazoline derivatives; production; medicaments containing
Prior art date: 2000-12-20

Application number

HR20030504A

Other languages

English (en)

Croatian (hr)

Inventor

Himmelsbach Frank

Langkope Elke

Blech Stefan

Jung Birgit

Baum Elke

Solca Flavio

Original Assignee

Boehringer Ingelheim Pharma Gmbh & Co.Kg.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-20

Filing date

2001-12-12

Publication date

2011-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030504(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-12-12 Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg.

2005-06-30 Publication of HRP20030504A2 publication Critical patent/HRP20030504A2/hr

2011-09-30 Publication of HRP20030504B1 publication Critical patent/HRP20030504B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

HR20030504A 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof HRP20030504B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10063435A DE10063435A1 (de)	2000-12-20	2000-12-20	Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PCT/EP2001/014569 WO2002050043A1 (de)	2000-12-20	2001-12-12	Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Publications (2)

Publication Number	Publication Date
HRP20030504A2 HRP20030504A2 (en)	2005-06-30
HRP20030504B1 true HRP20030504B1 (en)	2011-09-30

Family

ID=7667887

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20030504A HRP20030504B1 (en)	2000-12-20	2001-12-12	Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof

Country Status (39)

Country	Link
EP (2)	EP1345910B9 (is)
JP (1)	JP3827641B2 (is)
KR (1)	KR100852102B1 (is)
CN (1)	CN1277822C (is)
AR (1)	AR040524A1 (is)
AT (1)	ATE430136T1 (is)
AU (2)	AU2002219174B2 (is)
BE (1)	BE2014C009I2 (is)
BG (1)	BG66139B1 (is)
BR (1)	BRPI0116266B8 (is)
CA (1)	CA2432428C (is)
CY (2)	CY1109290T1 (is)
CZ (1)	CZ302721B6 (is)
DE (2)	DE10063435A1 (is)
DK (1)	DK1345910T3 (is)
EA (1)	EA006317B1 (is)
EE (1)	EE05244B1 (is)
ES (1)	ES2326617T3 (is)
FR (1)	FR14C0009I2 (is)
HR (1)	HRP20030504B1 (is)
HU (2)	HU228874B1 (is)
IL (2)	IL156277A0 (is)
LT (1)	LTC1345910I2 (is)
LU (1)	LU92370I2 (is)
ME (1)	ME02777B (is)
MX (1)	MXPA03005559A (is)
MY (1)	MY136086A (is)
NO (3)	NO325672B1 (is)
NZ (1)	NZ526918A (is)
PL (1)	PL214798B1 (is)
PT (1)	PT1345910E (is)
RS (1)	RS50860B (is)
SI (1)	SI1345910T1 (is)
SK (1)	SK287573B6 (is)
TW (1)	TWI295992B (is)
UA (1)	UA74614C2 (is)
UY (1)	UY27078A1 (is)
WO (1)	WO2002050043A1 (is)
ZA (1)	ZA200304141B (is)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MEP45508A (en)	1999-06-21	2011-02-10	Boehringer Ingelheim Pharma	Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) *	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en)	2002-04-19	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (de)	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es) *	2003-02-05	2004-12-14	Warner Lambert Co	Preparacion de quinazolinas substituidas
US7223749B2 (en)	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10307165A1 (de) *	2003-02-20	2004-09-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (de) *	2003-07-28	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
MXPA06002964A (es)	2003-09-16	2006-06-14	Astrazeneca Ab	Derivados de quinazolina como inhibidores de cinasa de tirosina.
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
AP2204A (en) *	2004-05-06	2011-02-07	Warner Lambert Co	4-phenylamino-quinazolin-6-yl-amides.
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006081741A1 (en) *	2005-02-05	2006-08-10	Piaoyang Sun	Quinazoline compounds or their medical salts and preparation and medical usage thereof
KR100832594B1 (ko) *	2005-11-08	2008-05-27	한미약품 주식회사	다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
WO2007054550A1 (en)	2005-11-11	2007-05-18	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
DK1948180T3 (da)	2005-11-11	2013-05-27	Boehringer Ingelheim Int	Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
EP1981863B1 (en)	2006-01-26	2012-10-10	Boehringer Ingelheim International GmbH	Process for preparing aminocrotonylamino-substituted quinazoline derivatives
NZ576065A (en)	2006-09-18	2011-12-22	Boehringer Ingelheim Int	Method for treating cancer harboring egfr mutations
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de)	2007-02-06	2009-11-18	Boehringer Ingelheim International GmbH	Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CN101939316B (zh)	2008-02-07	2013-10-02	贝林格尔.英格海姆国际有限公司	螺环杂环化合物、含有所述化合物的药物、其用途及其制备方法
BRPI0912170A2 (pt)	2008-05-13	2015-10-13	Astrazeneca Ab	composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
UY31867A (es)	2008-06-06	2010-01-29	Boehringer Ingelheim Int	Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
US8426430B2 (en)	2008-06-30	2013-04-23	Hutchison Medipharma Enterprises Limited	Quinazoline derivatives
US8648191B2 (en)	2008-08-08	2014-02-11	Boehringer Ingelheim International Gmbh	Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
JP5781934B2 (ja) *	2008-11-10	2015-09-24	ナショナルヘルスリサーチインスティテューツ	チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物
US20120157472A1 (en)	2009-01-14	2012-06-21	Boehringer Ingelheim International Gmbh	Method for treating colorectal cancer
CN102316875A (zh)	2009-02-13	2012-01-11	贝林格尔.英格海姆国际有限公司	用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
EP2429527A1 (en) *	2009-05-14	2012-03-21	Boehringer Ingelheim International GmbH	New combination therapy in treatment of cancer and fibrotic diseases
EP2429520A1 (en)	2009-05-14	2012-03-21	Boehringer Ingelheim International GmbH	New combination therapy in treatment of oncological and fibrotic diseases
PT2451445T (pt)	2009-07-06	2019-07-10	Boehringer Ingelheim Int	Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
EP2509592A1 (en)	2009-12-07	2012-10-17	Boehringer Ingelheim International GmbH	Bibw 2992 for use in the treatment of triple negative breast cancer
US8735409B2 (en) *	2009-12-21	2014-05-27	Qiang Zhang	Quinazoline derivatives
US20120107304A1 (en)	2010-04-27	2012-05-03	Boehringer Ingelheim International Gmbh	Combination therapy in treatment of oncological and fibrotic diseases
NO2608792T3 (is)	2010-08-26	2018-03-10
CN103476770B (zh) *	2010-11-25	2017-02-15	拉蒂欧制药有限责任公司	阿法替尼盐和多晶型物
SG10201913982WA (en)	2011-03-04	2020-03-30	Newgen Therapeutics Inc	Alkyne Substituted Quinazoline Compound And Methods Of Use
CN102918029B (zh)	2011-05-17	2015-06-17	江苏康缘药业股份有限公司	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US8828391B2 (en)	2011-05-17	2014-09-09	Boehringer Ingelheim International Gmbh	Method for EGFR directed combination treatment of non-small cell lung cancer
CN102838590B (zh) *	2011-06-21	2014-07-09	苏州迈泰生物技术有限公司	氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
US20150232457A1 (en)	2011-10-06	2015-08-20	Ratiopharm Gmbh	Crystalline forms of afatinib di-maleate
CN103073539B (zh) *	2011-10-26	2016-05-11	齐鲁制药有限公司	4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
SI2805940T1 (sl)	2012-01-17	2017-04-26	Astellas Pharma Inc	Pirazinkarboksamidna spojina
CN103772380A (zh) *	2012-10-23	2014-05-07	杨子娇	一类治疗房角狭窄的化合物及其用途
US20150368230A1 (en)	2013-02-01	2015-12-24	Boehringer Ingelheim International Gmbh	Radiolabeled quinazoline derivatives
HK1213818A1 (zh)	2013-04-05	2016-07-15	勃林格殷格翰国际有限公司	依帕列净的治疗用途
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es)	2013-04-05	2019-02-27	Boehringer Ingelheim Int	Usos terapéuticos de empagliflozina
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
DK2986304T3 (da)	2013-04-18	2022-04-04	Boehringer Ingelheim Int	Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
CN103254183B (zh) *	2013-05-10	2015-11-11	苏州明锐医药科技有限公司	阿法替尼的制备方法
CN103254182A (zh) *	2013-05-10	2013-08-21	苏州明锐医药科技有限公司	一种阿法替尼的制备方法
WO2014180271A1 (zh) *	2013-05-10	2014-11-13	苏州明锐医药科技有限公司	阿法替尼及其中间体的制备方法
WO2014183560A1 (zh) *	2013-05-16	2014-11-20	苏州明锐医药科技有限公司	阿法替尼及其中间体的制备方法
CN103242303B (zh) *	2013-05-16	2015-03-25	苏州明锐医药科技有限公司	阿法替尼的制备方法
CN104513229A (zh)	2013-09-28	2015-04-15	正大天晴药业集团股份有限公司	喹唑啉衍生物及其制备方法
CN103755688B (zh) *	2013-12-24	2015-11-18	江苏奥赛康药业股份有限公司	一种阿法替尼化合物的制备方法
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015103456A1 (en)	2014-01-02	2015-07-09	Teva Pharmaceuticals International Gmbh	Crystalline forms of afatinib di-maleate
CN105315263B (zh) *	2014-07-30	2018-11-27	正大天晴药业集团股份有限公司	阿法替尼中间体的合成方法
EP3023421A1 (en)	2014-11-21	2016-05-25	Sandoz Ag	Crystalline forms of afatinib dimaleate
CN105801568B (zh)	2015-01-15	2019-07-30	杭州普晒医药科技有限公司	阿法替尼一马来酸盐晶型及其制备方法和药物组合物
HK1244278B (zh)	2015-03-20	2020-04-17	正大天晴药业集团股份有限公司	喹唑啉衍生物的盐及其制备方法
CN105175400B (zh) *	2015-09-29	2018-04-10	河北神威药业有限公司	一种阿法替尼中间体的制备方法
WO2017141271A1 (en) *	2016-02-17	2017-08-24	Sun Pharmaceutical Industries Ltd.	Stable pharmaceutical composition of afatinib
CN106442793B (zh) *	2016-10-21	2019-05-24	河北神威药业有限公司	一种制备阿法替尼的中间体及其对映异构体的检测方法
CN109922813A (zh)	2016-11-10	2019-06-21	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途
TWI808958B (zh)	2017-01-25	2023-07-21	美商特普醫葯公司	涉及二芳基巨環化合物之組合療法
JP2021506974A (ja) *	2017-12-18	2021-02-22	スターングリーン、インク．	チロシンキナーゼ阻害剤として有用なピリミジン化合物
CN110437163A (zh) *	2018-05-03	2019-11-12	斯特恩格林公司	作为酪氨酸激酶抑制剂的嘧啶类化合物
MX2021003517A (es)	2018-09-25	2021-08-16	Black Diamond Therapeutics Inc	Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
CN109265449B (zh) *	2018-11-07	2021-11-23	沈阳工业大学	Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
KR20210107069A (ko)	2018-12-21	2021-08-31	다이이찌 산쿄 가부시키가이샤	항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CN109824657A (zh) *	2019-03-26	2019-05-31	石药集团中奇制药技术（石家庄）有限公司	一种二马来酸阿法替尼新晶型及其制备方法和应用
AU2020328598A1 (en)	2019-08-15	2022-03-03	Black Diamond Therapeutics, Inc.	Alkynyl quinazoline compounds
CN110590682A (zh) *	2019-10-14	2019-12-20	重庆医科大学	一种制备阿法替尼杂质的方法以及制备的杂质
WO2021094379A1 (en)	2019-11-12	2021-05-20	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023510426A (ja)	2020-01-20	2023-03-13	アストラゼネカ・アクチエボラーグ	癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
US20210369709A1 (en)	2020-05-27	2021-12-02	Astrazeneca Ab	EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN115894383B (zh) *	2021-09-30	2025-12-19	北京赛特明强医药科技有限公司	一种喹唑啉类化合物、组合物及其应用
KR20240168418A (ko)	2022-03-31	2024-11-29	아스트라제네카 아베	암 치료를 위한 akt 억제제와 조합된 표피 성장 인자 수용체(egfr) 티로신 키나아제 억제제
WO2023209084A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their application in the treatment of cancer
US20240116926A1 (en)	2022-04-28	2024-04-11	Astrazeneca Ab	Heteroaromatic compounds
KR20250029133A (ko)	2022-06-27	2025-03-04	아스트라제네카 아베	암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997038983A1 (en) *	1996-04-12	1997-10-23	Warner-Lambert Company	Irreversible inhibitors of tyrosine kinases
WO1999006378A1 (en) *	1997-07-29	1999-02-11	Warner-Lambert Company	Irreversible inhibitors of tyrosine kinases
DE19908567A1 (de) *	1999-02-27	2000-08-31	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2000051991A1 (en) *	1999-02-27	2000-09-08	Boehringer Ingelheim Pharma Kg	4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES
DE19911366A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2001077104A1 (de) *	2000-04-08	2001-10-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA986729B (en) *	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
DE19911509A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
MEP45508A (en) *	1999-06-21	2011-02-10	Boehringer Ingelheim Pharma	Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof

2000
- 2000-12-20 DE DE10063435A patent/DE10063435A1/de not_active Withdrawn
2001
- 2001-12-12 AU AU2002219174A patent/AU2002219174B2/en active Active
- 2001-12-12 PL PL361798A patent/PL214798B1/pl unknown
- 2001-12-12 KR KR1020037008246A patent/KR100852102B1/ko not_active Expired - Lifetime
- 2001-12-12 AT AT01271363T patent/ATE430136T1/de active
- 2001-12-12 NZ NZ526918A patent/NZ526918A/en not_active IP Right Cessation
- 2001-12-12 CN CNB018208665A patent/CN1277822C/zh not_active Expired - Lifetime
- 2001-12-12 HR HR20030504A patent/HRP20030504B1/xx not_active IP Right Cessation
- 2001-12-12 SK SK771-2003A patent/SK287573B6/sk not_active IP Right Cessation
- 2001-12-12 AU AU1917402A patent/AU1917402A/xx active Pending
- 2001-12-12 DE DE50114874T patent/DE50114874D1/de not_active Expired - Lifetime
- 2001-12-12 ES ES01271363T patent/ES2326617T3/es not_active Expired - Lifetime
- 2001-12-12 CA CA002432428A patent/CA2432428C/en not_active Expired - Lifetime
- 2001-12-12 EE EEP200300300A patent/EE05244B1/xx active Protection Beyond IP Right Term
- 2001-12-12 HU HU0301852A patent/HU228874B1/hu active Protection Beyond IP Right Term
- 2001-12-12 ME MEP-2008-595A patent/ME02777B/me unknown
- 2001-12-12 SI SI200130916T patent/SI1345910T1/sl unknown
- 2001-12-12 UA UA2003076821A patent/UA74614C2/uk unknown
- 2001-12-12 EP EP01271363.2A patent/EP1345910B9/de not_active Expired - Lifetime
- 2001-12-12 DK DK01271363T patent/DK1345910T3/da active
- 2001-12-12 EP EP09158964A patent/EP2112140A1/de not_active Withdrawn
- 2001-12-12 IL IL15627701A patent/IL156277A0/xx unknown
- 2001-12-12 WO PCT/EP2001/014569 patent/WO2002050043A1/de not_active Ceased
- 2001-12-12 PT PT01271363T patent/PT1345910E/pt unknown
- 2001-12-12 JP JP2002551540A patent/JP3827641B2/ja not_active Expired - Lifetime
- 2001-12-12 MX MXPA03005559A patent/MXPA03005559A/es active IP Right Grant
- 2001-12-12 EA EA200300671A patent/EA006317B1/ru not_active IP Right Cessation
- 2001-12-12 BR BRPI0116266A patent/BRPI0116266B8/pt not_active IP Right Cessation
- 2001-12-12 RS YUP-496/03A patent/RS50860B/sr unknown
- 2001-12-12 CZ CZ20031930A patent/CZ302721B6/cs not_active IP Right Cessation
- 2001-12-17 UY UY27078A patent/UY27078A1/es not_active Application Discontinuation
- 2001-12-19 MY MYPI20015767A patent/MY136086A/en unknown
- 2001-12-19 TW TW090131520A patent/TWI295992B/zh active
- 2001-12-19 AR AR20010105883A patent/AR040524A1/es active IP Right Grant
2003
- 2003-05-28 ZA ZA200304141A patent/ZA200304141B/en unknown
- 2003-06-03 IL IL156277A patent/IL156277A/en active Protection Beyond IP Right Term
- 2003-06-16 NO NO20032726A patent/NO325672B1/no active Protection Beyond IP Right Term
- 2003-06-19 BG BG107929A patent/BG66139B1/bg unknown
2009
- 2009-07-23 CY CY20091100793T patent/CY1109290T1/el unknown
2014
- 2014-01-30 FR FR14C0009C patent/FR14C0009I2/fr active Active
- 2014-01-31 LU LU92370C patent/LU92370I2/fr unknown
- 2014-02-06 LT LTPA2014005C patent/LTC1345910I2/lt unknown
- 2014-02-11 NO NO2014003C patent/NO2014003I2/no not_active IP Right Cessation
- 2014-02-12 HU HUS1400005C patent/HUS1400005I1/hu unknown
- 2014-02-12 CY CY2014008C patent/CY2014008I2/el unknown
- 2014-02-18 BE BE2014C009C patent/BE2014C009I2/fr unknown
2022
- 2022-07-01 NO NO2022028C patent/NO2022028I1/no unknown

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997038983A1 (en) *	1996-04-12	1997-10-23	Warner-Lambert Company	Irreversible inhibitors of tyrosine kinases
WO1999006378A1 (en) *	1997-07-29	1999-02-11	Warner-Lambert Company	Irreversible inhibitors of tyrosine kinases
US6127374A (en) *	1997-07-29	2000-10-03	Warner-Lambert Company	Irreversible inhibitors of tyrosine kinases
DE19908567A1 (de) *	1999-02-27	2000-08-31	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2000051991A1 (en) *	1999-02-27	2000-09-08	Boehringer Ingelheim Pharma Kg	4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES
DE19911366A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2001077104A1 (de) *	2000-04-08	2001-10-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Also Published As

Publication number	Publication date
HK1060571A1 (en)	2004-08-13
NO2014003I1 (no)	2014-06-02
AR040524A1 (es)	2005-04-13
RS50860B (sr)	2010-08-31
YU49603A (sh)	2006-05-25
EP1345910A1 (de)	2003-09-24
JP2004516283A (ja)	2004-06-03
SK7712003A3 (en)	2003-10-07
BG107929A (bg)	2005-01-31
CN1481370A (zh)	2004-03-10
CY2014008I2 (el)	2015-12-09
MXPA03005559A (es)	2004-10-14
CA2432428C (en)	2009-09-01
EP1345910B1 (de)	2009-04-29
ES2326617T9 (es)	2014-09-10
UA74614C2 (en)	2006-01-16
NO20032726D0 (no)	2003-06-16
CY2014008I1 (el)	2014-07-02
ZA200304141B (en)	2004-04-15
IL156277A0 (en)	2004-01-04
ME02777B (me)	2011-10-10
AU1917402A (en)	2002-07-01
CA2432428A1 (en)	2002-06-27
HRP20030504A2 (en)	2005-06-30
NO2022028I1 (no)	2022-07-01
BG66139B1 (bg)	2011-07-29
ATE430136T1 (de)	2009-05-15
DE10063435A1 (de)	2002-07-04
FR14C0009I2 (fr)	2014-11-14
SK287573B6 (sk)	2011-03-04
HU228874B1 (en)	2013-06-28
KR100852102B1 (ko)	2008-08-13
PT1345910E (pt)	2009-07-14
WO2002050043A1 (de)	2002-06-27
NO2014003I2 (no)	2015-10-19
TWI295992B (en)	2008-04-21
FR14C0009I1 (fr)	2014-03-07
CZ20031930A3 (cs)	2003-10-15
EE200300300A (et)	2003-10-15
ES2326617T3 (es)	2009-10-16
EP1345910B9 (de)	2014-06-04
KR20030071787A (ko)	2003-09-06
CY1109290T1 (el)	2014-07-02
MEP59508A (en)	2011-05-10
EE05244B1 (et)	2009-12-15
EA006317B1 (ru)	2005-10-27
LTPA2014005I1 (lt)	2022-05-25
CZ302721B6 (cs)	2011-09-21
DK1345910T3 (da)	2009-07-20
LTC1345910I2 (lt)	2022-06-10
HUP0301852A3 (en)	2008-03-28
NO20032726L (no)	2003-06-16
HUP0301852A2 (hu)	2003-09-29
PL214798B1 (pl)	2013-09-30
HUS1400005I1 (hu)	2017-08-28
LU92370I9 (is)	2019-01-17
NZ526918A (en)	2006-11-30
SI1345910T1 (sl)	2009-08-31
PL361798A1 (en)	2004-10-04
UY27078A1 (es)	2002-07-31
AU2002219174B2 (en)	2007-09-06
NO325672B1 (no)	2008-07-07
BRPI0116266B1 (pt)	2017-10-31
DE50114874D1 (de)	2009-06-10
LU92370I2 (fr)	2014-03-31
MY136086A (en)	2008-08-29
EP2112140A1 (de)	2009-10-28
BR0116266A (pt)	2004-02-17
IL156277A (en)	2009-12-24
BRPI0116266B8 (pt)	2021-07-27
BE2014C009I2 (is)	2021-02-04
EA200300671A1 (ru)	2004-06-24
CN1277822C (zh)	2006-10-04
JP3827641B2 (ja)	2006-09-27

Publication	Publication Date	Title
HRP20030504B1 (en)	2011-09-30	Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
YU491A (sh)	1994-01-20	3-aminopiperidinski derivati
FI962489A0 (fi)	1996-06-14	Morfoliini-ja tiomoforfoliinitakykiniinireseptoriantaginisteja
NO20062942L (no)	2006-06-23	Fremgangsmate for fremstilling av en fast, oralt anvendelig farmasoytisk sammensetning
WO2000071511A3 (en)	2001-08-09	INHIBITORS OF FACTOR Xa
DE69523169D1 (de)	2001-11-15	Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
GB9305282D0 (en)	1993-05-05	Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine
HUP9900926A2 (hu)	1999-09-28	Új (4-oxialkoxi-fenil)-3-oxi-piperidinek, szív- és veseelégtelenség kezelésére
TR200201413T2 (tr)	2003-02-21	Faktör Xa' nın inhibitörleri.
CO5300398A1 (es)	2003-07-31	Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek
TR199701173T1 (xx)	1998-03-21	Yeni arilglisinamid t�revleri, bunlar�n �retilmesine mahsus usul.
DE59510144D1 (de)	2002-05-08	Mittel und verfahren zur dauerhaften verformung von keratinfasern
NZ514542A (en)	2002-10-25	Vasopressin antagonists for the treatment of pulmonary hypertension
DK0698025T3 (da)	1998-08-24	Ampa-antagonister samt fremgangsmåde til behandling dermed
ATE440088T1 (de)	2009-09-15	Verfahren zur herstellung von 4-(3'-chlor-4'- fluoranilino)-7-methoxy-6-(3- morpholinopropoxy)chinazolin
CA2281918A1 (en)	1998-09-03	Oxazolidines as 5-ht2a-antagonists
DE59812576D1 (de)	2005-03-24	Verwendung von 1-substituierten isatinen zum färben von keratinhaltigen fasern
NO972938L (no)	1997-06-23	Farmasöytiske piperazinforbindelser
CO4340625A1 (es)	1996-07-30	Dihidropiridinas condensadas y su utilizacion para la produccion de preparados farmaceuticos
DE50003989D1 (de)	2003-11-13	Benzophenone und ihre verwendung als photoinitiatoren
RU2342363C2 (ru)	2008-12-27	Бензоилпиперидиновые соединения
NO963213L (no)	1997-02-03	Endotelinreseptorantagonister
ATE156117T1 (de)	1997-08-15	15-deoxyspergualine-analoge, verfahren in ihrer herstellung und ihre verwendung als immunosuppressiva
PA8524001A1 (es)	2002-07-30	Proceso para preparar 2-(4-piridil)amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas
MY128754A (en)	2007-02-28	Substituted 3-aryl-3-carboxyalkyl glutaramides, method for preparing same by 4-aryl-4-cyanoheptane dicarboxylic acid cyclisation, and use thereof for preparing 3-aryl-3-hydroxyalkylpiperidines

Legal Events

Date	Code	Title	Description
2005-06-30	A1OB	Publication of a patent application
2005-12-27	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2011-09-30	B1PR	Patent granted
2018-12-14	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20181130 Year of fee payment: 18
2019-12-13	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20191120 Year of fee payment: 19
2020-12-25	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20201207 Year of fee payment: 20
2022-01-04	PB20	Patent expired after termination of 20 years	Effective date: 20211212